10-Q: Walgreens Boots Alliance Reports Q1 2025 Loss Amidst Strategic Overhaul

Walgreens Boots Alliance reports a net loss for Q1 2025, driven by restructuring costs and fair value adjustments, while advancing strategic initiatives to optimize its footprint and stabilize pharmacy margins.

Summary

• Walgreens Boots Alliance (WBA) reported a net loss attributable to WBA of $265 million, or $0.31 per share, for the first quarter of fiscal year 2025, compared to a net loss of $67 million, or $0.08 per share, in the year-ago quarter.
• The current quarter's net loss was impacted by $252 million in after-tax costs related to the Footprint Optimization Program and a $152 million after-tax non-cash charge related to fair value adjustments on variable prepaid forward (VPF) derivatives related to the monetization of Cencora shares.
• Sales increased by 7.5% to $39.459 billion, driven by growth in the U.S. Retail Pharmacy and International segments.
• The company is executing a Footprint Optimization Program, planning to close approximately 900 to 1,000 stores primarily across the U.S. by the end of fiscal 2027, with 83 stores closed in the current quarter.
• WBA is evaluating options for VillageMD, including a potential sale or restructuring.
• The company repaid $1.2 billion of principal and interest on unsecured notes and $290 million on a senior unsecured multi-tranche delayed draw term loan credit facility.
• WBA sold shares of BrightSpring common stock for approximately $129 million.
• The company is exploring opportunities to obtain additional debt or other financing and amend or extend existing borrowings in anticipation of debt maturities and expiration of revolving credit facilities expected in fiscal 2026 and fiscal 2027.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reported net loss and ongoing restructuring efforts. While there are some positive aspects, such as sales growth and cost-saving initiatives, the overall financial performance is concerning.

Positives

• Sales increased by 7.5% to $39.459 billion, driven by growth in the U.S. Retail Pharmacy and International segments.
• The company is on track to deliver benefits to cash flow from the Footprint Optimization Program that will exceed cash closure costs.
• International segment sales increased 10.2 percent to $6.4 billion.
• U.S. Healthcare adjusted operating income improved by $121 million from the year-ago quarter to $25 million.
• The company is exploring opportunities to obtain additional debt or other financing and amend or extend existing borrowings in anticipation of debt maturities and expiration of revolving credit facilities expected in fiscal 2026 and fiscal 2027.

Negatives

• Walgreens Boots Alliance reported a net loss of $265 million in Q1 2025, compared to a net loss of $67 million in Q1 2024.
• The current quarter's net loss was impacted by $252 million in after-tax costs related to the Footprint Optimization Program and a $152 million after-tax non-cash charge related to fair value adjustments on variable prepaid forward (VPF) derivatives related to the monetization of Cencora shares.
• Retail sales, including the impact of store closures, decreased by 6.2 percent for the three months ended November 30, 2024.
• Operating loss for the three months ended November 30, 2024 was $325 million, a decrease of $110 million versus the year-ago quarter in the U.S. Healthcare segment.

Risks

• The company is dependent on funding from its subsidiaries to pay dividends and meet its obligations.
• The ability of the Company to meet its liquidity needs depends on, among other factors, the stability of global credit markets and the Company’s continued compliance with financial covenants, which in turn may be impacted by adverse litigation, the Company’s inability to monetize investments and other assets, underperformance and impairment of existing assets, poor operating performance, and other risks.
• The company is currently evaluating a variety of options with respect to VillageMD in light of ongoing investments by the Company in VillageMDs businesses and VillageMDs substantial ongoing and expected future cash requirements.
• The sale process or any of the aforementioned strategic opportunities could result in incremental goodwill or long-lived asset impairment charges.

Future Outlook

The company expects store closures to progress in the remainder of fiscal 2025 and anticipates the retail environment to remain challenging.

Management Comments

• The Company believes it is on track to deliver benefits to cash flow from the Footprint Optimization Program that will exceed cash closure costs.

Industry Context

The announcement comes as Walgreens Boots Alliance navigates a rapidly evolving healthcare and retail landscape, marked by increasing competition, changing consumer preferences, and reimbursement pressures. The strategic review and cost-cutting measures reflect a broader trend among major players in the pharmacy and healthcare sectors to streamline operations and focus on core competencies.

Comparison to Industry Standards

• CVS Health, a major competitor, has also been actively involved in optimizing its retail footprint, closing underperforming stores to focus on health services and digital capabilities.
• Amazon's entry into the pharmacy space with its acquisition of PillPack and expansion of Amazon Pharmacy has further intensified competition, pushing traditional players to innovate and adapt.
• Walgreens' focus on cost management and footprint optimization aligns with industry trends aimed at improving profitability and efficiency in a challenging environment.
• The company's investment in VillageMD and other healthcare ventures mirrors the broader industry shift towards integrated healthcare models that combine pharmacy, primary care, and other services.

Legal Proceedings

• The Company remains a defendant in multiple actions in federal courts alleging claims generally concerning the impacts of widespread opioid abuse.
• The Company is defending a number of claims, lawsuits, and investigations alleging that the Companys retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process.
• On March 19, 2024, the arbitrator issued a Final Award in the amount of $988 million including interest. The Company disputes the alleged claims and the Final Award in part because it believes it is in contravention of a contractual cap on damages, which limits damages to $79 million.
• On July 12, 2024, a purported shareholder filed a putative class action lawsuit in the United States District Court for the Northern District of Illinois ( Bhaila v. Walgreens Boots Alliance, Inc. , 24-cv-05907) against the Company and certain of its executives (together, for the purposes hereof, Defendants) alleging that Defendants violated securities laws by disseminating materially false and misleading statements and/or concealing material adverse facts concerning the Companys pharmacy division.
• Three purported shareholders have filed derivative suits in the United States District Court for the Northern District of Illinois ( Tobias v. Wentworth et al. , 24-cv-07755 (Aug. 27, 2024); Hollin v. Wentworth et al ., 24-cv-08244 (Sept. 10, 2024); Lovoi v. Wentworth et al. , 24-cv-09110 (Sept. 27, 2024)) against the Companys directors and certain of the Companys officers, and against the Company as a nominal defendant (together, for purposes hereof, Defendants), alleging that the individual Defendants breached their fiduciary duties to the Company by willfully or recklessly making and/or causing the Company to make false and misleading statements related to the Companys internal controls and overall expected performance, thereby artificially inflating the Companys stock price.
• On December 4, 2024, two purported shareholders filed a derivative suit in the United States District Court for the District of Delaware ( Switter v. Wentworth, et al. , 24-cv-01314 (Dec. 4, 2024)) against certain of the Company's current and former directors and officers, and against the Company as a nominal defendant (together, for purposes hereof, the Defendants).

Related Party Transactions

• The Company has a long-term pharmaceutical distribution agreement with Cencora pursuant to which the Company sources branded and generic pharmaceutical products from Cencora.
• Related party purchases, net with Cencora were $20.039 billion for the three months ended November 30, 2024.

Stakeholder Impact

• Shareholders: The net loss and strategic changes may concern shareholders, but the company's efforts to improve efficiency and profitability could be viewed positively in the long term.
• Employees: The Footprint Optimization Program will result in store closures and employee severance, impacting employees in affected locations.
• Customers: Store closures may reduce access to pharmacy and retail services for some customers, while investments in healthcare services could improve access for others.
• Suppliers: Changes in vendor relationships and procurement strategies could impact suppliers.
• Creditors: The company's debt repayment and exploration of additional financing options will be of interest to creditors.

Next Steps

• Continue executing the Footprint Optimization Program.
• Stabilize pharmacy margins through contracting with partners.
• Re-evaluate the U.S Retail Pharmacy sales strategy.
• Continue to monetize non-core assets and manage liquidity.
• Evaluate options with respect to VillageMD.

Key Dates